Mescaline
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- Mescaline
- Molecular weight
- 211.26
- Structure (SMILES)
- COc1cc(CCN)cc(OC)c1OC
- 2 3 4 5 trimethoxyphenyl ethanamine
- 2-(3,4,5-trimethoxyphenyl)ethanamine
- cabazitaxel 25 mg m
- cisplatin 40 mg m
- FOLFIRI (m)
- FOLFOX-6 (m)
- M (psychedelic)
- m psychedelic
- mescaline
- Mescaline
- MESCALINE [HSDB]
- MESCALINE [MART.]
- MESCALINE [MI]
- Mescaline [WHO-DD]
- Mescaline 100mg
- Mescaline 200mg
- Mescaline 400mg
- Mescaline 800mg
- mescaline hsdb
- mescaline mart
- mescaline mi
- mescaline who dd
- Morte-mescaline
- nsc 30419
- NSC-30419
- CAS registry numbers
- 54-04-6
- ChEMBL ID
- CHEMBL26687
- InChIKey
- RHCSKNNOAZULRK-UHFFFAOYSA-N
- PubChem compound IDs
- 4076
- FDA ingredient codes (UNII)
- RHO99102VC
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- mescaline
- Type
- Natural product
Mechanisms of action
- Action
- Agonist
- Action type
- Agonist
- Target
- 5-HT2A receptor
- Gene symbol
- HTR2A
- Protein identifier
- P28223
- Median affinity
- 5.59
- Affinity units
- pEC50
- Event
- alcohol abuse
- Reports
- 2
- Reporting signal score
- 15.1582
- Event
- substance abuse
- Reports
- 2
- Reporting signal score
- 13.9682
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 53.71
- Calculated partition coefficient (ALogP)
- 1.21
- Calculated partition coefficient (XLogP)
- 0.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 15
- Molecular formula
- C11H17NO3
- Monoisotopic mass
- 211.12084340
- Natural product
- Yes
- Recorded assays
- 134
- Active assays
- 52
Active assay types
- Confirmatory
- Hallucinogens
- Serotonin Receptor Agonists
Related records
Trials (252)
- 1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer
- 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
- A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy
- A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers
- A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers
- A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
- A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy
- A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
- A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
- A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI
- A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
- A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
- A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
- A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
- A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
- A Study of ABT-165 in Subjects With Solid Tumors
- A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
- A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer